Welcome to the ICD‐10 code for sarcopenia

Aims Sarcopenia has recently been given an ICD-10 code. However, there have been no systematic investigations regarding the prevalence or prognostic value of sarcopenia in cardiovascular disease (CVD) according to the international consensus definition. The present study was performed to investigate the prevalence and prognostic value of sarcopenia in elderly patients with CVD. Methods and resultsThe study population consisted of 1603 admitted patients aged ≥ 65 years (74.4 ± 6.2 years, 1049 men) with CVD. Sarcopenia was defined according to the recommended diagnostic algorithm of the Asia Working Group for Sarcopenia. The endpoint for the study was all-cause mortality. The overall sarcopenia prevalence rate was 29.7% (19.6% in men and 48.7% in women). The prevalence rates of sarcopenia across major diagnostic categories were as follows: acute coronary syndrome, 17.8%; post-cardiac surgery, 31.8%; and heart failure, 35.2%. During the 2.3 ± 2.1-year follow-up period, 175 deaths occurred. Patients with sarcopenia showed higher risk of allcause mortality compared with non-sarcopenic patients (adjusted hazard ratio: 1.44; 95% confidence interval: 1.01 -2.05; P = 0.044).Conclusions Sarcopenia is highly prevalent among elderly patients with CVD and is associated with increased mortality risk.

show abstract

“…Sarcopenia is becoming a major health issue with the aging of the world's population [1][2][3][4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Sarcopenia: Prevalence and Prognostic Implications in Elderly Patients with Cardiovascular Disease

Kamiya

Hamazaki²,

Matsuzawa³

et al. 2017

JCSM Clinical Reports

View full text Add to dashboard Cite

show abstract

“…Sarcopenia is defined as low physical function in persons with a low muscle mass (27)(28)(29)(30). Jones et al (31) reported that sarcopenia was present in 15% of COPD patients.…”

Section: Figure 2 Mechanisms Of Sarcopenia In Persons With Copdmentioning

confidence: 99%

Frailty, Comorbidity, and COPD

Charbek

Espiritu

Nayak

et al. 2018

The Journal of nutrition, health and aging

Self Cite

View full text Add to dashboard Cite

“…It has been proposed that sarcopenia might indeed represent a promising organ-specific pathophysiological background for defining a muscular condition of clinical relevance 11) . In this context, it is noteworthy that the recent allocation of a specific International Statistical Classification of Diseases and Related Health Problems (ICD-10) code to sarcopenia 12) demonstrated how this condition has all the necessary characteristics for theoretically framing a nosological entity. However, the creation of an ICD-10 code for sarcopenia has surely solved part of the issue related to the implementation of the condition in the clinical setting.…”

Section: What Is Sarcopenia?mentioning

confidence: 99%

Physical Frailty and Sarcopenia: Development of a Framework for Supporting Interventions Against Incident Mobility Disability

Cesari

2017

Ann Geriatr Med Res

View full text Add to dashboard Cite

In 2014, the Innovative Medicines Initiative funded a 48-million Euros project entitled "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" (SPRINTT). The SPRINTT consortium federates partners from academia, industry, and the private sector to address an important gap in the geriatric field: the lack of a standardized and clinically relevant definition of sarcopenia. In particular, the SPRINTT project aims to involve all major stakeholders in the framing of a skeletal muscle-specific risk profile that exposes the individual at risk of negative health-related outcomes (in particular, disability), is amenable to benefiting from preventive interventions, and meets the standards requested by regulatory agencies. During the first year of activity, the SPRINTT consortium has implemented a "Physical Frailty & Sarcopenia" (PF&S) condition that considers existing evidence and regularly exchanges information with the European Medicines Agency. This condition is currently the study objective of a 3-year randomized controlled trial in multiple countries across Europe. The trial aims to verify whether a multicomponent intervention (based on physical activity and nutritional counseling) can prevent the onset of mobility disabilities in community-dwelling older persons with PF&S. The present article provides an overview of the SPRINTT background and rationale and explains the details of the PF&S condition.

show abstract

Welcome to the ICD‐10 code for sarcopenia

Abstract: The new ICD‐10‐CM (M62.84) code for sarcopenia represents a major step forward in recognizing sarcopenia as a disease. This should lead to an increase in availability of diagnostic tools and the enthusiasm for pharmacological companies to develop drugs for sarcopenia.

Cited by 708 publications

References 76 publications

Sarcopenia: Prevalence and Prognostic Implications in Elderly Patients with Cardiovascular Disease

Sarcopenia: Prevalence and Prognostic Implications in Elderly Patients with Cardiovascular Disease

Frailty, Comorbidity, and COPD

Physical Frailty and Sarcopenia: Development of a Framework for Supporting Interventions Against Incident Mobility Disability

Contact Info

Product

Resources

About